Absolute Return Capital’s Pacira BioSciences PCRX Stock Holding History

Absolute Return Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-9,912	Closed	-$694K	–	1336
2014 Q1	$694K	Buy	+9,912	New	+$674K	0.01%	745

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Absolute Return Capital's PCRX Position: Q2 2014 in Review

Absolute Return Capital sold out of Pacira BioSciences (PCRX) in Q2 2014, closing a stake of 9,912 shares — an estimated $694K sold.

Absolute Return Capital first reported a position in PCRX in Q1 2014 and held it in 1 quarter. The position peaked at $694K in Q1 2014. 191 funds tracked by Wall St. Rank hold PCRX as of Q2 2014.

Absolute Return Capital reported no remaining Pacira BioSciences position as of Q2 2014 after selling out during the quarter.
Absolute Return Capital sold 9,912 Pacira BioSciences shares in Q2 2014, an estimated $694K.
Absolute Return Capital first reported a position in Pacira BioSciences in Q1 2014 and held it in 1 quarter.
Absolute Return Capital's Pacira BioSciences position peaked at $694K in Q1 2014.
191 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2014.

Based on Absolute Return Capital's 13F filing for Q2 2014, filed 14 Aug 2014.